The dilemma concerning the use of cerebral va sodilating agents in the treatment of neurological disorders has not been resolved to everyone's sat isfaction and still remains controversial. In a recent review of cerebral vasodilators by Cook and James (1981) , they point out that "there is now consider able evidence from double-blind clinical trials, [that] some of [these] drugs produce mental im provements in the patients with dementia. " Despite the paucity of controlled studies that consistently show therapeutic value of these agents, especially in patients with cerebrovascular disease (Hymans, 1978) , many such agents have been shown to in crease regional cerebral blood flow (rCBF) when given i. v. (Gottstein, 1965; Meyer et al., 1965; McHenry et al., 1970; Oleson and Paulson, 1971: Herrschaft, 1975; Capon et al., 1977) . The effect of oral administration of these agents on rCBF has re-demonstrated 90 min after a single 600-mg dose of oral papaverine. Increases of 5.09% and 8.69%, respectively, were recorded immediately after a single 100-mg dose of i. v. papaverine. FO also increased significantly (p ,s; 0.001) for both drug forms when compared to that of pla cebo. Placebo produced only a slight increase (not sig nificant) with both the oral and i. v. groups. The data show that both oral and i. v. papaverine are equally effective in increasing rCBF in normal subjects. Key Words: Papav erine, oral and intravenous-Regional cerebral blood flow -Xenon-I 33 inhalation.
ceived little attention (Meyer et al., 1971; Wang and Obrist, 1975; Shaw and Meyer, 1978) .
Before a clinical trial of the therapeutic useful ness of these agents can be carried out, one must determine if oral therapy will itself improve brain circulation, as well as produce clinical improve ment, and if such improvement correlates with ce rebral vasodilatation. We do not intend to pursue the controversy regarding the clinical effectiveness of these agents, or the pathophysiological effects of cerebral vasodilating agents; this has been dis cussed elsewhere (Klassen, 1972; McHenry, 1972 . The objective of this study is to demonstrate the relative bioequivalence of oral and i. v. papav erine on rCBF in normal human subjects.
METHODS

Study subjects
Subjects evaluated for this study were 15 healthy adult volunteers! who were right-handed males from 38 to 62 years old, and who were obtained by informal local ad-! Except for one subject (no. 3) with unsuspected tularemia who was included in error (see Results); this subject was not, "healthy volunteer."
vertising. Evaluations performed prior to this study con sisted of a medical history, physical examination, clinical laboratory determinations, and serial blood sampling for serum papaverine determinations. Excluded from this study were subjects with a history of risk factors for dis eases associated with arteriosclerosis, namely hyperten sion, arteriosclerotic heart disease, transient ischemic at tacks, stroke, and diabetes mellitus. Also excluded were subjects with posttraumatic or postinfective brain damage, presenile dementia, cerebral neoplasm, neuro syphilis, anemia, or renal or hepatic disease. Written in formed consent was obtained from each study subject and the protocol was approved by the institutional review board of the Bowman Gray School of Medicine.
Thirteen healthy adult male subjects were studied on 2 consecutive test days. For I week prior to and throughout the duration of each test day, any other drugs thought to affect cerebral circulation were not administered. On each test day, a baseline rCBF measurement was taken from each subject, which was followed by the adminis tation of an i. v. placebo or a placebo capsulet according to a randomized schedule. A second post-placebo rCBF determination followed. After a I-h "washout," active i.v. papaverine hydrochloride or Pavabid Hp® capsulets (Arnold et aI., 1977; Lee et aI., 1978) were administered, followed by a final rCBF measurement.
Due to the objective nature of the rCBF data recorded, the automatic computerized analysis of these data, and the need to minimize radiation exposures to the volunteer subjects, the study was conducted single-blind. Each pa tient received, sequentially, i.v. placebo (saline) followed by i.v. papaverine hydrochloride on one test day, and placebo capsulets followed by Pavabid HP capsulets on the second test day. The dose form (i. v. or capsulets) received on test day I was randomly assigned for each subject. Day 2 medications were the alternate dose form.
Dosage preparation
Medications in a form meeting the requirements of single-blind administration were prepared and supplied by the sponsor. All medications used in the study were administered directly to the subject by the investigators. The dosage of each form was the same for all subjects. Pavabid HP capsulets (300 mg) and identically appearing placebo capsulets were provided in bulk by Marion Lab oratories, Inc. Each subject was issued two capsulets by the investigator during each phase of the study, main taining the single-blind for dosage forms. The dose of Pavabid HP was two capsulets (600 mg), and the dose of placebo capsulets was two similarly appearing capsulets. The papaverine hydrochloride i. v. solution concentration was 30 mg/ml (Eli Lilly), and the dose was 3.3 ml or 100 mg. Intravenous administration was carried out by a 5-min infusion via brachial vein with a Harvard pump ap paratus. Placebo i.v. dosage was 3.3 ml normal saline, infused in the same manner as the papaverine hydrochlo ride solution.
Study design and statistical methodology
CBF data were assessed for differences between the two treatments (i. v. and oral) and between the treatment effects of the drug when compared with the placebo and baseline, and for right and left hemispheric rCBF differ ences. This was accomplished by parametric three-factor analysis of variance. Correlations between serum papav erine levels and rCBF values were evaluated. Since rCBF data were recorded from the source directly onto mag netic tape, the retrieval and analysis of these data were conducted according to standardized procedures. Subject demographic data, clinical laboratory results, and side effects were recorded on original subject case report forms, and analysis was conducted by the investigators and the sponsor in collaboration. Side effects were ana lyzed for treatment differences in both quantitative and qualitative response.
rCBF measurements rCBF measurements were performed by the xenon-133 inhalation rCBF method developed by Obrist et al. (1975) , as modified for use in our laboratory (McHenry et aI., 1978) . Measurements of rCBF were performed with the subject lying relaxed in the supine position, with eyes closed and in a dimly lighted room. No conversation oc curred, except to occasionally reassure the subject. All procedures and the nature of measurements and equip ment were carefully and clearly explained to the subject prior to the measurement. The equipment and methods used to measure rCBF by the xenon inhalation method consisted of a 16-channel Harshaw TA SC-5 system with the PDP-II-OS computer and the Obrist computer pro gram. Eight regions were measured over each side of the subject's head. The studies were performed by having the subject breathe 7-8 mCi xenon-133/L for a period of I min from a IO-L Radx Ventl-con® spirometer. The xenon in-air ' was administered via a Bennett Benefit® mask containing a port for withdrawal of continuous sam ples for radioisotopic analysis of the air curve and for the estimation of carbon dioxide levels. End-tidal air sam pling was taken directly from the mouthpiece over a 2-in scintillation probe in the shielded spirometer to obtain the air curve for xenon. End-tidal air was extracted over the air probe at a rate of 1.5 Llmin taking less than 2 s to reach the air probe from the mouthpiece. This exposure to xenon-133 resulted in an estimated maximum exposure of 0.14 rads to the lungs, 0.01 rads to blood and gonads, and 0.1 rads to fatty tissues. Sixteen Harshaw Ml2 SHA1I3/4-X probes were used, which consisted of 0.5 x 0.5-in NaI crystals fitted with I-in diameter lead collimation. An additional outer coat of lead foil was added to reduce leakage at the base of the probe housing. Eight probes were mounted in fixed positions in a modified motorcycle helmet on each side of the head. A stable reference at the orbito-meatal line was maintained when placing the helmet on each subject. Standard probe positions had been established with a plastic-embedded skull. Stray radiation from the lungs was reduced by shielding the patient with a lead apron. All exposed tubing was enclosed in lead foil. Blood pres sure was monitored with a sphygmomanometer cuff. End-tidal carbon dioxide was monitored with a Goddard capnograph. Recording windows were set to include both X-ray and gamma peaks. At the end of I min of xenon inhalation, the subject was switched to room air alone and exhaled xenon for a period of 10 min during the actual rCBF measurement. During this time, counts were accumulated from the air and head probes and stored in the computer. At the end of the rCBF study, the raw and interpolated head and air curve data were displayed on a Te ktronics 40 I 0-1 terminal along with a digital display of peak counts. Peak counts for the head curve were -30,000 cpm.
After the rCBF measurement was completed and the head curves visualized, the study data were analyzed with the Obrist computer program. For rCBF analysis all unedited data were processed through the TASC-5 dy namic analyzer linked to the PDP-I 1-05 computer. The computer program was an iterative technique furnished by Tennecomp Systems and consisted of the scanner TP-5200-11-0040 version of the Obrist equations. This yielded rCBF results separated into the following parameters: the CBF initial slope index of Obrist, the 2-minute-slope index (ISI2) of Risberg (1975) , the fast-clearing compartment or flow gray (FG) in ml!100 g/min; the slow-clearing com ponent or flow white (FW) in ml!100 glmin; the mean flow (MF) in ml!100 g/min, and gray matter weight (GW) in percent. Results of all rCBF parameters were then printed on a teletype.
Baseline and placebo reBF measurements
The subject had a baseline rCBF measurement and then rested quietly for 1 h to facilitate xenon washout. The subject next received the single-blind placebo dose of i.v. saline or placebo capsulets, according to the ran domization schedule. Following the single-blind admin istration of placebo infusion or capsulets, a second rCBF determination was conducted. The baseline rCBF mea surement was initiated immediately after infusion of i.v. saline or 90 min following ingestion of the placebo cap sulet. A 60-min xenon washout period then followed.
Drug reBF measurements
Following the 60-min washout, the subject received i. v. papaverine hydrochloride infusion (100 mg) or Pavabid HP capsulets (600 mg), respective to the placebo dose form that same test day. The next rCBF determination followed immediately after papaverine hydrochloride in fusion, or 90 min following ingestion of Pavabid HP cap sulets. After a 24-h medication washout, subjects re turned for test day 2. Test day 2 proceeded exactly as test day 1, except for the utilization of the alternate med ication. Following the final rCBF determination, blood and urine samples were collected for determination of clinical laboratory data and papaverine blood levels.
Blood sampling for papaverine levels
Blood samples for papaverine levels were drawn during each test day as follows. Intravenous test day: (a) im mediately preceding infusion of the saline placebo; (b) immediately after infusion; (c) at the midpoint (5-10 min) of the post-placebo rCBF measurement; (d) at the con clusion of the rCBF determination. Corresponding blood samples were drawn (a) immediately preceding the pa paverine hydrochloride infusion; (b) immediately after in fusion; (c) at the midpoint of the active drug rCBF de termination; and (d) at the end of the rCBF measurement.
On the capsulet test day samples were drawn for pa paverine determinations 
RESULTS
Study population
The investigators performed studies on 15 sub jects, but only 13 could be used for evaluation. Sub ject no. 3 completed the capsulet test day only. During the first study day the subject reported re curring symptoms of tularemia (chills and fever in termittently) from a 14-year history, and declined to participate in the second (i. v.) test day. Because each subject was to serve as his own control, only the capsulet data are included in the analysis.
Subject no. 7 completed the study; however, a computer error during analysis of the i. v. test day data inadvertently erased a section of data related to the drug phase, and a complete analysis was not possible. Therefore, this subject's i.v. data were ex cluded . All of the remaining subjects received both dose forms during the study and were included in the analysis.
reBF results
FG (or the calculated actual blood flow in gray matter, measured in milliliters of blood per 100 grams of gray matter per minute) was used as the criterion for documenting significant changes after drug administration. Using our reBF method (McHenry et aI., 1978) , we considered FG to be the best parameter for demonstrating regional blood flow changes or differences. End-tidal Peoz values remained within the normal limits for the laboratory during all reBF measurements. Since this report only evaluates left and right hemisphere reBF values, more "regional" effects of papaverine have not been discussed. The problem of extracerebral contamination, particularly in the low temperof rontal region, using the xenon inhalation method to measure reBF, might tend to complicate a more detailed analysis of our data and may not serve the overall purpose of this study.
The mean individual calculated FG values in each hemisphere for each subject and hemispheric mean values are shown in Ta bles 1 and 2 and are sum marized in Fig. 1 . This graph shows responses to each test procedure of the left and right hemisphere and demonstrates the increase in reBF for both ac tive drugs as compared to baseline and placebo measurements.
It is apparent that FG increased significantly fol lowing administration of both drugs when compared to their respective baselines. Increases of 10.53 % and 13.94% (left and right hemispheres, respec tively) from baseline to drug study were detected in the Pavabid HP group, and increases of 5.09 % and 8.69% (left and right hemispheres, respectively) Total flow gray by test period, measured in left and right hemispheres, in ml1100 g/min. NA, not applicable.
from baseline to drug study occurred in the i. v. pa paverine group. From placebo to drug rCBF mea surements, there were increases of 8.18% and 12.27% (left and right hemispheres, respectively) demonstrated in the Pavabid HP group, and in creases of 8.82% and 9.52% (left and right hemi spheres, respectively) occurred in the i. v. papav erine group. Analysis of variance shows that this increase is significant (p ",; 0.001) for both drugs. FG also increased significantly (p ",; 0.001) for both drugs when compared to those after their respective placebos. The placebos produced only a slight, nonsignificant increase with the capsulet group, and a slight, nonsignificant decrease in the i. v. group.
When we compared the oral drug day to the i.v. day, there were no significant differences among any of the three test periods (i.e. , baseline to base line, placebo to placebo, or drug to drug). In fact, the patterns of mean FG values were significantly (p = 0.05) correlated from one test day to the other. These results demonstrate the bioequivalence of the two forms of papaverine hydrochloride. There was no significant relationship between the age of the subject and the effectiveness of the drug, nor was Total flow gray by test period, measured in left and right hemispheres, in ml/lOO g/min. there any correlation between the age of the subject and his initial rCBF.
Papaverine blood levels
Papaverine blood levels were obtained before and after dosing at all test sessions. A total of eight blood samples was drawn on each test day from each patient. Samples 1-5 were blank controls, drawn from the subject to preserve the blind of the study. The final three samples (nos. 6, 7, and 8) represented papaverine blood levels immediately preceding, midway through, and immediately fol lowing the final rCBF determination. The papav erine levels measured in sample nos. 7 and 8, drawn midway through and following the rCBF measurement, respectively, were used to investi gate a possible correlation between blood levels and increased rCBF. Papaverine assays were reported in micrograms papaverine base per milliliters of plasma. The actual plasma papaverine levels in sample nos. 7 and 8 for each subject's test day are listed in Ta ble 3.
As shown in Ta ble 3, mean papaverine serum levels are higher during the i. v. papaverine test day than during the Pavabid HP day at the time of sam pling. These figures do not correlate with the in creases in rCBF, either on an individual patient basis or when compared with the group means. However, these levels may differ due to the time of sampling for the subjects in the two groups (i.e. , im mediately post-dose i.v. and 90 min post-dose cap sulets). Although the i. v. group papaverine levels were higher immediately following infusion, the Pavabid HP blood levels were sustained at the in dicated level for a longer period of time prior to rCBF testing and therefore may have had a similar vasodilatory effect due to intracellular activity.
This rationale may be supported by noting that the overall mean value of the serum papaverine level of sample no. 8 (obtained after completion of the rCBF testing), shown in Ta ble 3, dropped only slightly in the Pavabid HP group, but dropped pre cipitously in the i. v. group, bringing the mean values closer together after this 10-15-min delay. Tr ansient side effects of nausea, abdominal dis tress, and headache occurred in two subjects in this study. Both subjects reporting these side effects re covered quickly after the study, and no permanent or adverse condition resulted.
CONCLUSIONS
A single-blind study was conducted in 13 right handed normal male subjects to compare the effects of Pavabid HP and i.v. papaverine hydrochloride on rCBF. Six xenon-133 inhalation rCBF measure ments were performed on each subject; three tests-baseline, placebo, and drug evaluations were performed on 2 separate days. The drugs, Pav abid HP or i. v. papaverine hydrochloride, were ran domized for first-day administration. rCBF, mea sured as FG, increased significantly (p � 0. 001) from baseline with both drugs. FG also increased significantly (p � 0.001) for both drugs when com pared to placebo.
No significant relationship was shown between the age of the subject and the effectiveness of the drug, nor was there any correlation between the age of the subject and his initial baseline flows. There were no serious side effects or adverse reactions during the study. The data show that both Pavabid HP and i.v. papaverine hydrochloride are equally effective in increasing rCBF in normal subjects. The next step in determining the clinical effectiveness of papaverine is to repeat this study in a group of patients with early multi-infarct dementia. A com bined study with rCBF and neuropsychological testing would show whether this agent not only in creases rCBF, but if it improves mental function at the same time. Such a study could demonstrate the therapeutic usefulness of cerebral vasodilators in the treatment of neurological symptoms due to ce rebrovascular insufficiency.
